Free Trial
NASDAQ:NXTC

NextCure Q1 2026 Earnings Results & Report

NextCure logo
$6.40 +0.17 (+2.73%)
Closing price 11/13/2026 04:00 PM Eastern
Extended Trading
$6.48 +0.07 (+1.17%)
As of 11/13/2026 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

NextCure beat analyst earnings expectations in its Q1 2026 results, released May 7, 2026. The company reported EPS of -$1.87 versus the -$2.1050 consensus estimate.

Earnings Announcement Details

Quarter
Q1 2026
Report Date
Time
Before Market Opens
Conference Call
7:00 AM ET

NextCure EPS Results

Actual EPS
-$1.87
Consensus EPS
-$2.1050
Beat/Miss
Beat by +$0.2350
One Year Ago EPS
N/A
EPS Beat Rate
4 of last 8 quarters

NextCure Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

NextCure Q1 2026 Earnings FAQ

NextCure (NASDAQ:NXTC) reported earnings of -$1.87 per share for Q1 2026, beating the consensus estimate of -$2.1050. The report was announced on Thursday, May 7, 2026.

NextCure Earnings Headlines

NextCure (NASDAQ:NXTC) Rating Lowered to Sell at Wall Street Zen
The investigation Porter spent tens of thousands to document
Porter Stansberry flew the Porter and Co. team 3,300 miles to Dublin to investigate a 17-year investing experiment called Project Prophet - and documented everything on film. Rooted in the laws of physics, this quantitative approach challenges conventional wealth-building wisdom. With 17 years of verified data behind it, Porter calls it unlike anything he has seen in nearly 30 years in the business.tc pixel
NextCure CMO Departs Amid Pending Avere Merger
NextCure Faces Court Review of Reverse Stock Split
See More NextCure Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like NextCure? Sign up for Earnings360's daily newsletter to receive timely earnings updates on NextCure and other key companies, straight to your email.

About NextCure

NextCure (NASDAQ:NXTC) is a clinical-stage biopharmaceutical company focused on developing treatments for cancer. The company researches immunomedicines designed to influence how immune cells recognize and respond to tumors; it does not market approved commercial products.

Its discovery work has included antibody-based and small-molecule candidates aimed at immune-related targets such as Siglec-15, LAIR-1 and CBL-B. NextCure has used its FIND-IT platform to identify and investigate potential therapeutic targets and drug candidates.

Founded in 2015, NextCure is based in Beltsville, Maryland. Its work is centered on oncology research and clinical development.

View NextCure Profile